How to access Entyvio from the UAE — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A UAE patient with moderately-to-severely active ulcerative colitis or Crohn's disease may receive a prescription for Entyvio (vedolizumab) from their treating gastroenterologist. Entyvio is FDA-approved in the United States and manufactured by Takeda. It is a humanised monoclonal antibody that selectively binds the α4β7 integrin, giving it a gut-selective mechanism that differentiates it from systemic immune-suppressing biologics. Vedolizumab is locally registered in the UAE for IBD indications, so many patients access it through hospital pharmacies; the named-patient pathway is relevant where the specific dose form (IV vs new subcutaneous pen) is not locally stocked, or where an insurer or supply context makes private import the faster route.
This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
The clinical situation
Entyvio is administered either as an IV infusion (weeks 0, 2, 6, then every 8 weeks maintenance) or — in newer labeling — as a subcutaneous injection for maintenance after IV induction. Your treating gastroenterologist confirms diagnosis, endoscopic and clinical activity, TB and infection screening, and the monitoring plan per FDA labeling.
Is Entyvio legally importable into the UAE?
Yes — through the UAE Ministry of Health and Prevention (MoHAP) named-patient framework, with parallel authority through DoH Abu Dhabi and DHA Dubai depending on the prescribing facility. The pathway allows a UAE-licensed physician to import a medicine not locally registered for the specific indication or dose form when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent registered alternative fits, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.
For Entyvio specifically, the named-patient channel is used primarily where the subcutaneous dose form is clinically preferred but not in stock, where the paediatric dose setup is not locally supported, or where institutional procurement timing is not workable for the patient.
How the pathway works, step by step
- Consultation with your treating gastroenterologist. Diagnosis, activity documentation, and clinical rationale.
- Pre-treatment screening. TB, hepatitis, and infection screening per labeling.
- MoHAP named-patient application. The physician or hospital pharmacy files the application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner.
- Cold-chain shipment. Entyvio ships at 2–8°C with continuous temperature monitoring.
- Arrival and first dose. The infusion facility receives the IV product, or the pharmacy dispenses the SC pen for caregiver/patient use after training.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming IBD diagnosis, activity, prior therapies, and Entyvio as the indicated treatment
- Verification of their UAE medical licence
- Patient identifier
- Pre-treatment screening confirmation
- Planned induction and maintenance regimen, IV vs SC pathway
Reserve Meds provides a physician documentation kit that bundles the templates MoHAP reviewers expect to see for gut-selective integrin biologics.
Costs and timing
Entyvio's US cash-pay reference price for a single IV induction vial sits in a broad indicative range of roughly USD 7,500–9,000; the SC maintenance pen is priced per pen at a similar magnitude. International cold-chain logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.
Indicative timing — not guaranteed — for first dose after cohort intake opens is approximately 10–21 days from the moment a complete application is submitted. Maintenance doses ship on a rolling basis.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Entyvio specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoHAP review.
- Logistics. Cold-chain, temperature-monitored shipment.
- Concierge case lead. A named point of contact.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating gastroenterologist.
Frequently asked
Isn't Entyvio already registered in the UAE? Yes, and many IBD patients access it through local hospital pharmacies. Named-patient rationale applies where the specific dose form (for example, SC pen) isn't stocked, where the paediatric context needs originator-specific supply, or where institutional timing doesn't fit the clinical need.
What about vedolizumab biosimilars? If a locally available biosimilar is clinically appropriate and approved, your physician may recommend that instead. Reserve Meds coordinates originator Entyvio access when clinically requested.
Is this legal? Yes, when executed through the MoHAP named-patient framework with appropriate documentation.
Will private insurance cover this? Cash-pay is the default. Some UAE insurers reimburse named-patient imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Entyvio coordination in the UAE.
Add me to the Entyvio waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.